Youtube Pro Stock Picks

Click here to search for stock quotes, financial statistics and more.

or

Life Sciences

NGEN stock
Analysts Life Sciences ngen
This analyst loves NervGen Pharma

In a March 31 report, Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials NASDAQ:NGEN), saying the firm remains focused primarily on the company’s clinical progress rather than near-term financial results. Uddin said NervGen recently completed its end-of-Phase 2 meeting […]

EDT stock
Analysts Life Sciences edt
Is Spectral Medical a buy?

Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$3.50 target on Spectral Medical (Spectral Medical Stock Quote, Chart, News, Analysts, Financials TSX:EDT) following publication of the company’s TIGRIS septic shock study in The Lancet Respiratory Medicine. In a March 24  note, Uddin described the data as exceptionally strong after Spectral announced full […]

WELL Health
Share Tweet linked In Share

Get Stock Picks from the Pros.
In your Inbox.

Market research firm Global Industry Analysts says the global market for 3D medical imaging will reach (US) $5.9 Billion by 2017.

2008 was supposed to be Medipattern’s (TSXV:MKI) big year. The Toronto based company, which de...

Protech

Shares of CardioComm (TSXV:EKG) were on fire today after the company announced it had cleared an imp...

If you want telecom you go to Ottawa. If you want oil and gas technology, go to Alberta. When it com...

Neptune Technologies

Neptune Technologies (TSXV:NTB) yesterday reported its Q3, 2012 results. The numbers appeared to be ...

In combination with Gemzar, a nucleoside used in chemotherapy and marketed by Eli Lilly, eight of thirteen patients enrolled in a recent REOLYSIN study showed stability for twelve weeks or more.

The long and winding road. Investors know progress in biotech can be painfully slow. Oncolytics Biot...

Could Quebec's CAE Inc. eventually become as well know for its medical simulation technologies as its flight simulators?

CAE Inc. (TSX:CAE), which was founded in 1947 in Saint-Hubert, Quebec has built a billion dollar bus...

Dr. Lars Ekman, Executive Chairman and President of Protox Therapeutics. Byron Capital Healthcare and Biotech Analyst Douglas Loe believes the market is

In a recent note to clients, Byron Capital’s Healthcare and Biotech Analyst Douglas Loe reiter...

A map of canola production regions in Canada. Canada produces 20 percent of the world’s canola.

For Bioexx (TSX:BXI) shareholders, 2011 was a year to forget. Shuffling management, delays in bringi...

After a tough few years, the first half of 2011 showed signs of hope for shareholders of AEterna Zen...

With another remarkable year of revenue growth, can SXC Health's Mark Thierer repeat as Cantech Letter's Tech Stock Exec of the Year in 2011?

SXC Health’s (TSX:SXC) meteoric rise, accomplished primarily through acquisition, has been not...

There are many people who believe Canadian technology stocks are undervalued. Of course, as John May...

For Vancouver’s Verisante (TSXV:VRS), the waiting game is almost over. The company’s ski...

Those closely watching the TSX Venture Exchange’s volume leaders lately may have noticed a new...

There are big markets and then there are big markets. While still miniscule, revenue wise, Vancouver...

Howard Verrico

All your eggs in one basket. Most investors know innately that this is a bad strategy. Investors int...

Don Cherry and Ottawa Senators owner Eugene Melnyk teaming up? Not quite. While Don Cherry is still ...

Vancouver based QLT now has 67% of its market cap in cash and short term investments.

When it comes to spending money, nobody does it quite like the biotech sector. The Texas Hold-Em sty...

After a tough few years, 2011 is shaping up quite nicely for shareholders of Quebec City’s Aet...

WELL Health
Share Tweet linked In Share

Get Stock Picks from the Pros. In your Inbox.

TRENDING

All Trending →
LMN stock

AI won’t kill Lumine Group, this analyst says

 March 10, 2026
KXS Stock

Kinaxis named a “Top Pick” for 2026 by this analyst

 March 9, 2026
CSU stock

This investor never liked Constellation Software. He does now.

 March 8, 2026
GTII stock

This cannabis stock is a “Top Pick” for 2026, analyst says

 March 2, 2026
TRUL Stock

Is Trulieve Cannabis a buy right now?

 March 2, 2026